Cowen Upgrades Bioverativ Inc (BIVV) to Outperform; Positive on TNT009

Cowen upgraded Bioverativ Inc (NASDAQ: BIVV) from Market Perform to Outperform with a price target of $80.00 (from $47.00).

Analyst Eric Schmidt commented, "We are upgrading BIVV shares from Market Perform to Outperform. We believe the recent acquisition of True North and orphan candidate TNT009 for cold agglutinin disease is a game changer that dramatically improves Bioverativ's pipeline, growth potential, and diversification. We view TNT009 as a highly-innovative, low-risk candidate with >$1.5B in sales potential. Our new price target is $80/shr."

For an analyst ratings summary and ratings history on Bioverativ Inc click here. For more ratings news on Bioverativ Inc click here.

Shares of Bioverativ Inc closed at $60.31 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades United Internet (UTDI:GR) (UDIRY) to Buy
• Kepler Cheuvreux Upgrades IONOS (IOS:GY) to Buy
• Nomura/Instinet Upgrades YTL Power International (YTLP:MK) to Buy